Investor Presentation on Unaudited Consolidated Financial Results for the quarter ended June 30, 2026`
RESULTS
▼ Concern Flagged
MEDIUM RISK
📅 Filed on BSE: 21 Jul 2026, 04:52 PM IST · BSE ID: 20786a3b-e4a8-40e1-aa55-32d4f93c101d
View Original BSE Filing (PDF)
💡
In Simple Terms
Anthem Biosciences' quarterly profit and revenue decreased, but its cash holdings increased and profit margins improved.
🤖 AI Summary
- Anthem Biosciences' Q1 FY27 consolidated Profit After Tax (PAT) decreased 11.7% YoY to ₹1,199 Mn.
- Revenue from Operations for Q1 FY27 was ₹4,182 Mn, a 22.6% decline from ₹5,402 Mn in Q1 FY26.
- EBITDA stood at ₹1,755 Mn in Q1 FY27, with EBITDA margins at 39.6%, up from 38.1% in Q1 FY26.
- Net Cash position as of June 30, 2026, was ₹17,197 Mn, an increase from ₹7,848 Mn as of June 30, 2025.
- CRDMO segment revenue was ₹3,408 Mn, while Specialty Ingredients contributed ₹774 Mn to Q1 FY27 revenues.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Profit after tax (Q1FY27)
₹1,199 Mn
-11.7%
Revenue from Operations (Q1FY27)
₹4,182 Mn
-22.6%
EBITDA (Q1FY27)
₹1,755 Mn
-18.1%
EBITDA Margins (Q1FY27)
39.6%
153 bps
Net Cash (June 30, 2026)
₹17,197 Mn
🏢 How This Affects the Company
Consolidated Revenue from Operations declined by 22.6% YoY, driven by reductions in both CRDMO and Specialty Ingredients segments, reflecting shifts in customer delivery schedules.
Profit After Tax decreased by 11.7% YoY to ₹1,199 Mn. However, EBITDA margins improved to 39.6% from 38.1% in Q1 FY26, and the company's Net Cash position increased to ₹17,197 Mn.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results presentation.
👤
Who Is Affected
Shareholders are affected by the company's Q1 FY27 financial performance, which includes a decrease in Profit After Tax to ₹1,199 Mn and reduced revenue.
🔍
Management Signal
Management indicates commitment to sustaining revenue growth aligned with long-term historical performance and maintaining industry-leading margin profile through cost efficiencies.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — evaluate if revenue recovery aligns with management's commentary.
CRDMO and Specialty Ingredients segment performance — track growth in key business areas.
EBITDA and PAT margins — monitor continued improvement and stability in profitability.
MEDIUM RISK
Significant YoY revenue and profit decline presents a near-term business risk, despite management's positive outlook for later quarters.
💡 Investor Takeaway
Anthem Biosciences reported Q1 FY27 consolidated Profit After Tax of ₹1,199 Mn, down 11.7% YoY, on a 22.6% decline in Revenue from Operations to ₹4,182 Mn. EBITDA margins improved to 39.6%, and Net Cash grew to ₹17,197 Mn. Management signals strong underlying demand for later in the year.
⚖️ Strengths & Concerns
✅ Positives
- EBITDA margins for Q1 FY27 improved to 39.6% from 38.1% in Q1 FY26, indicating disciplined cost efficiencies and yield optimisation.
- Net Cash position significantly increased to ₹17,197 Mn as of June 30, 2026, from ₹7,848 Mn as of June 30, 2025.
⚠️ Concerns
- Revenue from Operations for Q1 FY27 decreased 22.6% YoY to ₹4,182 Mn, impacting the top-line performance.
- Profit After Tax for Q1 FY27 declined by 11.7% YoY to ₹1,199 Mn from ₹1,358 Mn in Q1 FY26.
📅 Company Track Record
Anthem Biosciences' Q1 FY27 net profit of ₹1,199 Mn represents a decline from the ₹1,358 Mn reported in Q1 FY26. Past filings context for Q1 FY27 had already indicated a net profit decrease of 11.7% YoY.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Anthem Biosciences' consolidated net profit in Q1 FY27?
Anthem Biosciences reported a consolidated Profit After Tax of ₹1,199 Mn for Q1 FY27.
How much did Anthem Biosciences' revenue from operations decline in Q1 FY27?
Revenue from Operations for Anthem Biosciences in Q1 FY27 decreased by 22.6% to ₹4,182 Mn compared to Q1 FY26.
What was Anthem Biosciences' EBITDA margin in Q1 FY27?
Anthem Biosciences' EBITDA margin for Q1 FY27 was 39.6%, an improvement of 153 bps from 38.1% in Q1 FY26.
What was Anthem Biosciences' Net Cash position as of June 30, 2026?
As of June 30, 2026, Anthem Biosciences maintained a Net Cash position of ₹17,197 Mn.
What were the revenues for Anthem Biosciences' CRDMO and Specialty Ingredients segments in Q1 FY27?
For Q1 FY27, CRDMO business delivered ₹3,408 Mn in revenues, and Specialty Ingredients delivered ₹774 Mn.
Questions based on this BSE filing only. For information purposes.